These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 21829064

  • 21. [Surgical treatment of an advanced GIST the age of imatinib].
    Fernández JA, Parrilla P.
    Cir Esp; 2009 Jul; 86(1):3-12. PubMed ID: 19539273
    [Abstract] [Full Text] [Related]

  • 22. Gastrointestinal stromal tumor.
    Gupta P, Tewari M, Shukla HS.
    Surg Oncol; 2008 Aug; 17(2):129-38. PubMed ID: 18234489
    [Abstract] [Full Text] [Related]

  • 23. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 24. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.
    J Clin Oncol; 2008 Feb 01; 26(4):626-32. PubMed ID: 18235122
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD.
    Semin Oncol; 2001 Oct 01; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [Abstract] [Full Text] [Related]

  • 27. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE, Blanke CD.
    Clin Adv Hematol Oncol; 2005 Aug 01; 3(8):647-57. PubMed ID: 16167051
    [Abstract] [Full Text] [Related]

  • 28. [An update on surgical treatment for gastrointestinal stromal tumor].
    Ishikawa T, Kanda T, Kosugi S, Yajima K, Hatakeyama K.
    Gan To Kagaku Ryoho; 2011 May 01; 38(5):722-7. PubMed ID: 21566430
    [Abstract] [Full Text] [Related]

  • 29. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.
    Med Sci Monit; 2007 Nov 01; 13(11):CR515-522. PubMed ID: 17968300
    [Abstract] [Full Text] [Related]

  • 30. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R.
    Histopathology; 2005 Jul 01; 47(1):41-7. PubMed ID: 15982322
    [Abstract] [Full Text] [Related]

  • 31. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY.
    Chin Med J (Engl); 2010 Jan 20; 123(2):131-6. PubMed ID: 20137358
    [Abstract] [Full Text] [Related]

  • 32. Two cases of complete response after imatinib mesylate treatment of advanced GIST.
    Papaxoinis G, Nikolaou M, Lianos E, Gaglia A, Economopoulos T, Pectasides D.
    Anticancer Res; 2006 Jan 20; 26(6C):4869-72. PubMed ID: 17214353
    [Abstract] [Full Text] [Related]

  • 33. Gastrointestinal stromal tumour treated with neoadjuvant imatinib.
    Loughrey MB, Mitchell C, Mann GB, Michael M, Waring PM.
    J Clin Pathol; 2005 Jul 20; 58(7):779-81. PubMed ID: 15976351
    [Abstract] [Full Text] [Related]

  • 34. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.
    Am J Surg Pathol; 2009 Feb 20; 33(2):218-26. PubMed ID: 18830121
    [Abstract] [Full Text] [Related]

  • 35. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M, Ruka W.
    J Surg Oncol; 2006 Mar 15; 93(4):304-11. PubMed ID: 16496358
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR.
    Zhonghua Yi Xue Za Zhi; 2006 Nov 21; 86(43):3064-7. PubMed ID: 17288838
    [Abstract] [Full Text] [Related]

  • 38. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
    Heinrich MC, Corless CL.
    J Surg Oncol; 2005 Jun 01; 90(3):195-207; discussion 207. PubMed ID: 15895440
    [Abstract] [Full Text] [Related]

  • 39. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
    Vrbanec D, Petricević B, Majerović M, Stern-Padovan R, Belev B, Skegro M, Herceg D, Plestina S, Dedić-Plavetić N, Jakić-Razumović J.
    Lijec Vjesn; 2006 Jun 01; 128(5-6):161-6. PubMed ID: 16910417
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.